- Enzon Pharmaceuticals Inc.
- NPS Pharmaceuticals Inc.
- Mera Pharmaceuticals Inc.
- Ancile Pharmaceuticals Inc.
- Cengent Therapeutics Inc.
- GeneFormatics Inc.
- Elixir Pharmaceuticals Inc.
- Centagenetix Inc.
- Oxford GlycoSciences PLC
- Cambridge Antibody Technology Group PLC
- UCB Celltech
- Schering-Plough Corp.
- Neurocrine Biosciences Inc.
- Eyetech Inc.
- Amgen Inc.
- AstraZeneca PLC
- NPS / Enzon merger: withdrawn
- Mera acquires Ancile in stock swap
- Structural Bioinformatics, GeneFormatics merge
- Elixir acquires Centagenetix in stock swap
- NPS Pharmaceuticals completes $103mm FOPO
- Pfizer, Neurocrine end agreement for indiplon
- Pfizer develops Eyetech's Macugen
- Amgen develops NPS Pharmaceuticals' calcium receptor tech.
- AstraZeneca, NPS Pharmaceuticals end five-year CNS deal
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.